Vol. 19/No. 3 | OncologyLive

Clinical Testing of Pan-TRK Inhibitor Progresses Across Multiple Tumor Types

February 13, 2018

The pan-TRK inhibitor entrectinib (RXDX101) is being tested simultaneously in multiple locally advanced or metastatic solid tumor types as a treatment for patients harboring fusions involving the NTRK1/2/3, ROS1, or ALK genes.

Bounty of Novel Drugs Ushers In New Era for ALK-Positive NSCLC

February 13, 2018

ALK inhibitors have followed a rapid trajectory from bench to bedside, taking over from chemotherapy as standard frontline treatment for patients with advanced non– small-cell lung cancer with ALK gene rearrangements.

Better Utilization of Broad Panel NGS Possible in 2018

February 13, 2018

A recent study of oncologists’ use of next-generation sequencing to test for actionable genetic mutations reveals a stark gap between the appropriateness and the actual utilization of these tests.

Focus Moves to Earlier Settings in Melanoma

February 12, 2018

Novel systemic therapies in the neoadjuvant and adjuvant settings have shown promising outcomes for locally advanced melanoma and may reduce the proportion of patients who need complete lymphadenectomy.

Immunotherapy Tops CRISPR Agenda

February 01, 2018

The gene-editing tool known as CRISPR may eventually enable oncology investigators to create methods for killing tumors directly, but thus far, the focus is on enhancing forms of immunotherapy already in clinical practice.

Biomarkers Go Beyond "All or None" Equation

January 31, 2018

The FDA’s recent approvals of novel anti-PARP agents as maintenance therapy for patients with previously treated advanced ovarian cancer highlight an issue that has received inadequate attention in the peer-reviewed oncology literature.